1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  11:35 2022-06-29 am EDT
1.790 EUR   -3.24%
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the Extraordinary shareholder meeting (translation for information purposes)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox S.A. Announces Executive Changes

05/16/2022 | 01:30am EDT

NicoxSA announced that its Board of Directors appointed Andreas Segerros as Chief Executive Officer of Nicox S. A on May 13th, 2022, effective from June 1st, 2022, following the Board’s decision to end the mandate of Michele Garufi, who has been Chairman, Chief Executive Officer and Co-Founder of the Company since its creation in 1996. Michele Garufi will remain as Board member of Nicox SA. Andreas Segerros has spent most of his career in global pharma, with executive positions (R&D, Marketing and Business Development) in the U.S., Europe and Japan, at Pharmacia, Pharmacia & Upjohn and Ferring, with the focus on specialty Pharma, ophthalmology in particular. As Global Head of Ophthalmology at Pharmacia, Andreas launched XALATAN® (latanoprost), making it the industry’s first billion-dollar ophthalmic drug. His venture capital experience comes from being Partner at the Scandinavian group Sunstone Capital, and also co-founded Eir Ventures. Andreas has made numerous investments in successful companies in Europe and the U.S.


© S&P Capital IQ 2022
All news about NICOX SA.
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E..
PU
06/15NICOX : How to participate in the Extraordinary shareholder meeting
PU
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
AQ
06/03Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
MT
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
GL
More news
Financials
Sales 2022 9,03 M 9,45 M 9,45 M
Net income 2022 -20,3 M -21,3 M -21,3 M
Net cash 2022 2,49 M 2,60 M 2,60 M
P/E ratio 2022 -3,81x
Yield 2022 -
Capitalization 77,4 M 81,0 M 81,0 M
EV / Sales 2022 8,30x
EV / Sales 2023 6,69x
Nbr of Employees 33
Free-Float 89,1%
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,79 €
Average target price 11,50 €
Spread / Average Target 542%
EPS Revisions
Managers and Directors
Andreas Rutger Segerros Chief Executive Officer
Sandrine Gestin Vice President-Finance
Michele Garufi Chairman
José Boyer Head-Research & Development
Doug Hubatsch Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-27.59%84
MERCK KGAA-27.89%74 911
KYOWA KIRIN CO. LTD.-0.96%12 244
SK BIOPHARMACEUTICALS CO., LTD.-24.38%4 503
BETTA PHARMACEUTICALS CO., LTD.-23.71%3 809
YUHAN CORPORATION-10.31%2 957